GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » FCF Yield %

Myriad Genetics (Myriad Genetics) FCF Yield % : -10.59 (As of May. 02, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Myriad Genetics's Trailing 12-Month Free Cash Flow is $-184.2 Mil, and Market Cap is $1,739.0 Mil. Therefore, Myriad Genetics's FCF Yield % for today is -10.59%.

The historical rank and industry rank for Myriad Genetics's FCF Yield % or its related term are showing as below:

MYGN' s FCF Yield % Range Over the Past 10 Years
Min: -12.18   Med: 4.08   Max: 13.87
Current: -10.59


During the past 13 years, the highest FCF Yield % of Myriad Genetics was 13.87%. The lowest was -12.18%. And the median was 4.08%.

MYGN's FCF Yield % is ranked worse than
62.07% of 232 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.4 vs MYGN: -10.59

Myriad Genetics's FCF Margin % for the quarter that ended in Dec. 2023 was -34.69%.


Myriad Genetics FCF Yield % Historical Data

The historical data trend for Myriad Genetics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics FCF Yield % Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.68 5.96 0.03 -12.87 -10.71

Myriad Genetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.43 -11.98 -4.15 -12.03 -15.85

Competitive Comparison of Myriad Genetics's FCF Yield %

For the Diagnostics & Research subindustry, Myriad Genetics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics's FCF Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's FCF Yield % falls into.



Myriad Genetics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Myriad Genetics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-184.2 / 1720.686
=-10.71%

Myriad Genetics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-68.2 * 4 / 1720.686
=-15.85%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myriad Genetics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Myriad Genetics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics (Myriad Genetics) Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Executives
Richard Bryan Riggsbee officer: Chief Financial Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Nicole Lambert officer: Chief Operating Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Margaret Ancona officer: SVP, Chief of Staff 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong officer: Chief Legal Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman officer: Chief People Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro director
Dale Muzzey officer: Chief Scientific Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Kevin Richard Haas officer: Chief Technology Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk officer: Chief Accounting Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Rashmi Kumar director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jayne B. Hart officer: Executive VP Human Resources 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jerry S Lanchbury officer: Senior V.P. - Research 320 WAKARA WAY, SALT LAKE CITY UT 84108